Top Stories
The findings could help refine patient selection and shape the design of future stroke trials.
Rytelo, competes with Bristol Myers Squibb's Reblozyl, is already approved to treat transfusion-dependent anaemia in patients with lower-risk myelodysplastic syndromes.
One-man company Mithril developed a proof-of-principle for a bispecific antibody treatment for a rare muscular dystrophy in less than 18 months by using Claude to manage operations.
The therapy, which targets GIP, GLP-1 and glucagon, outperformed Novo's GLP-1 receptor agonist both in terms of A1C reductions and weight loss.
Vaccine sales fell 6% to £2.6 billion, with revenue from Shingrix slipping 6% to £780 million, mainly due to its performance in China.
Conference News
The PLATINUM-Truveta retrospective cohort analysis compared the effectiveness of semaglutide 2.4 mg and resmetirom on liver enzymes and cardiometabolic markers in people with MASHNew post hoc data fro...
ALS (amyotrophic lateral sclerosis) is a life-threatening neurodegenerative disease characterized by a highly variable rate of progression among affected individualsThe Company believes implementation...
WATERTOWN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address ...
ProQR to present its ADAR-mediated RNA editing approach and progress toward next-generation editing oligonucleotides at TIDES Europe plenary sessionAX-0810 Phase 1 data to be featured in two poster pr...
BOSTON, Oct. 28, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target natural regulatory po...
